Qrons Inc. (QRON)
USD 0.15
(-3.23%)
USD 0.15
(-3.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 643.67 Thousand USD | 2.23% |
| 2022 | 629.62 Thousand USD | -21.49% |
| 2021 | 801.95 Thousand USD | 44.82% |
| 2020 | 553.74 Thousand USD | -63.48% |
| 2019 | 1.51 Million USD | -61.17% |
| 2018 | 3.9 Million USD | 178.3% |
| 2017 | 1.4 Million USD | 748.49% |
| 2016 | 165.37 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 86.37 Thousand USD | -39.92% |
| 2024 Q2 | 79.25 Thousand USD | -8.24% |
| 2023 FY | 683.75 Thousand USD | 8.6% |
| 2023 Q3 | 439.55 Thousand USD | 1777.0% |
| 2023 Q1 | 36.94 Thousand USD | -92.79% |
| 2023 Q2 | 23.41 Thousand USD | -36.61% |
| 2023 Q4 | 143.76 Thousand USD | -67.29% |
| 2022 Q2 | 31.06 Thousand USD | -51.12% |
| 2022 Q4 | 512.55 Thousand USD | 2183.01% |
| 2022 FY | 629.62 Thousand USD | -21.49% |
| 2022 Q1 | 63.55 Thousand USD | -90.8% |
| 2022 Q3 | 22.45 Thousand USD | -27.73% |
| 2021 Q1 | 38.36 Thousand USD | -85.12% |
| 2021 FY | 801.95 Thousand USD | 44.82% |
| 2021 Q4 | 690.48 Thousand USD | 2178.3% |
| 2021 Q2 | 42.79 Thousand USD | 11.56% |
| 2021 Q3 | 30.3 Thousand USD | -29.19% |
| 2020 FY | 553.74 Thousand USD | -63.48% |
| 2020 Q1 | 218.93 Thousand USD | -63.14% |
| 2020 Q2 | 13.58 Thousand USD | -93.79% |
| 2020 Q3 | 63.42 Thousand USD | 366.76% |
| 2020 Q4 | 257.78 Thousand USD | 306.42% |
| 2019 Q3 | 459.74 Thousand USD | 130.84% |
| 2019 Q2 | 199.15 Thousand USD | -24.42% |
| 2019 Q1 | 263.51 Thousand USD | -88.02% |
| 2019 FY | 1.51 Million USD | -61.17% |
| 2019 Q4 | 594.01 Thousand USD | 29.21% |
| 2018 Q3 | 534.31 Thousand USD | -21.8% |
| 2018 FY | 3.9 Million USD | 178.3% |
| 2018 Q2 | 683.25 Thousand USD | 39.83% |
| 2018 Q1 | 488.62 Thousand USD | -63.38% |
| 2018 Q4 | 2.19 Million USD | 311.51% |
| 2017 Q2 | 19.36 Thousand USD | 1691.77% |
| 2017 Q1 | 1081.00 USD | -99.32% |
| 2017 FY | 1.4 Million USD | 748.49% |
| 2017 Q4 | 1.33 Million USD | 2667.53% |
| 2017 Q3 | 48.21 Thousand USD | 148.95% |
| 2016 Q3 | 5480.00 USD | 0.0% |
| 2016 Q4 | 159.89 Thousand USD | 2817.7% |
| 2016 FY | 165.37 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 51.8% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 87.234% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 97.822% |
| Nascent Biotech, Inc. | 2.22 Million USD | 71.134% |
| Rebus Holdings, Inc. | 664 Thousand USD | 3.061% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.272% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -65.229% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.879% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -54.924% |
| Skye Bioscience, Inc. | 13.54 Million USD | 95.249% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.258% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 86.912% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -145.935% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.248% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 77.928% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 57.142% |
| Mesoblast Limited | 5.9 Million USD | 89.094% |
| Marizyme, Inc. | 19.23 Million USD | 96.654% |
| Genus plc | 147.7 Million USD | 99.564% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 92.668% |
| Pharming Group N.V. | 225.49 Million USD | 99.715% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 68.581% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 52.02% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 92.281% |
| ContraFect Corporation | 56.88 Million USD | 98.869% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 85.4% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 56.472% |
| IMV Inc. | 37.7 Million USD | 98.293% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 76.932% |
| MultiCell Technologies, Inc. | 567.42 USD | -113339.251% |
| ONE Bio Corp. | 6.44 Million USD | 90.011% |
| Accustem Sciences Inc. | 3.74 Million USD | 82.819% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.251% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -21.001% |
| Q BioMed Inc. | 3.43 Million USD | 81.27% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.396% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 75.503% |
| Biomind Labs Inc. | 994.18 Thousand USD | 35.256% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.352% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 63.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 90.419% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 65.475% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2674.708% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 95.98% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 64.924% |
| GB Sciences, Inc. | 1.42 Million USD | 54.687% |
| Alpha Cognition Inc. | 9.7 Million USD | 93.368% |
| HST Global, Inc. | 140.9 Thousand USD | -356.81% |
| CSL Limited | 3.44 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 42.78% |
| Halberd Corporation | 74.84 Thousand USD | -760.048% |
| Enzolytics Inc. | 2.17 Million USD | 70.467% |
| Agentix Corp. | 1.37 Million USD | 53.076% |
| Resverlogix Corp. | 12.71 Million USD | 94.936% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 82.368% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.958% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 38.345% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 73.235% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 59.244% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 81.096% |
| AVAX Technologies, Inc. | 7.31 Million USD | 91.195% |
| Zenith Capital Corp. | 8.94 Million USD | 92.802% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.922% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -3594.834% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 73.784% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -275.302% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 66.491% |
| Kadimastem Ltd | 2.41 Million USD | 73.293% |
| Helix BioMedix, Inc. | 1.97 Million USD | 67.36% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 94.077% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.198% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -254.672% |
| LadRx Corporation | 3.81 Million USD | 83.114% |
| Cell Source, Inc. | 4.32 Million USD | 85.118% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 30.301% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 30.301% |
| NovAccess Global Inc. | 2.46 Million USD | 73.906% |
| Affymax, Inc. | 39.38 Million USD | 98.366% |
| Itoco Inc. | 919.14 Thousand USD | 29.97% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 84.813% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 42.477% |
| Mobile Lads Corp. | 554.54 Thousand USD | -16.073% |
| CytoDyn Inc. | 18.05 Million USD | 96.436% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2457.42% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -192.477% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 54.664% |
| SYBLEU INC | 160.87 Thousand USD | -300.108% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 64.561% |
| International Stem Cell Corporation | 5.27 Million USD | 87.788% |
| Bioxytran, Inc. | 3.82 Million USD | 83.15% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1122.744% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -3064.12% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.225% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 60.218% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 12.524% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 79.31% |
| Neutra Corp. | 243.82 Thousand USD | -163.996% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 96.313% |
| PureTech Health plc | 144.59 Million USD | 99.555% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 96.859% |
| IXICO plc | 4.7 Million USD | 86.325% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 92.683% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.453% |
| CSL Limited | 3.89 Billion USD | 99.983% |
| Cellectis S.A. | 97.32 Million USD | 99.339% |